Treatment patterns and associated factors in 14,668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme

Diabetes, Obesity and Metabolism Jul 18, 2019

Nicolucci A, et al. - Because information on treatment patterns in individuals with type 2 diabetes in many nations are sparse, researchers reported treatment data from DISCOVER, a global, prospective, observational study program for patients with type 2 diabetes initiating a second-line glucose-lowering therapy. In 14,668 patients from 37 countries across six regions, first- and second-line treatments were evaluated. Metformin monotherapy and combinations of metformin with a sulphonylurea were the most common first-line therapies. Metformin combinations with other agents, including dipeptidyl peptidase-4 (DPP-4) inhibitors or sulphonylureas, were the most common second-line therapies among patients prescribed first-line metformin monotherapy. According to findings, first-line metformin monotherapy was less common than expected, and in some regions of the world, the use of newer second-line therapies was uncommon. The socioeconomic status of patients has been associated with patterns of treatment, suggesting that choices of therapy are influenced by cost and access. Choice of second-line therapy after metformin monotherapy was impacted by both clinical and non-medical factors.

Go to Original

Sign-up to continue reading. It is free & takes less than 2 mins

  • 45 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Free & unlimited access to original articles and quizzes
  • Nonloggedinlock icon
    Secure: we never sell your data
This article is only available to members. Are you a doctor? Click here to signup for free.
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen